WO2023172891A3 - Biomarkers for combination therapy for er+ breast cancer - Google Patents

Biomarkers for combination therapy for er+ breast cancer Download PDF

Info

Publication number
WO2023172891A3
WO2023172891A3 PCT/US2023/063825 US2023063825W WO2023172891A3 WO 2023172891 A3 WO2023172891 A3 WO 2023172891A3 US 2023063825 W US2023063825 W US 2023063825W WO 2023172891 A3 WO2023172891 A3 WO 2023172891A3
Authority
WO
WIPO (PCT)
Prior art keywords
individual
breast cancer
therapy
combination therapy
biomarkers
Prior art date
Application number
PCT/US2023/063825
Other languages
French (fr)
Other versions
WO2023172891A2 (en
Inventor
Matthew J. Ellis
Meenakshi ANURAG
Charles M. Perou
Original Assignee
Baylor College Of Medicine
The University Of North Carolina At Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine, The University Of North Carolina At Chapel Hill filed Critical Baylor College Of Medicine
Publication of WO2023172891A2 publication Critical patent/WO2023172891A2/en
Publication of WO2023172891A3 publication Critical patent/WO2023172891A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Embodiments of the disclosure concern methods and compositions that facilitate determination of a suitable therapy for an individual in need thereof. In specific embodiments, the individual has ER+ breast cancer of a specific subtype that renders them suitable for a particular therapy and/or renders them unsuitable for a particular therapy. In specific cases, gene expression analysis determines that an individual is of Luminal B subtype and the individual is suited for combination therapy of one or more aromatase inhibitors and one or more selective estrogen receptor degraders (SERDs) and/or is not suitable for chemotherapy.
PCT/US2023/063825 2022-03-07 2023-03-07 Biomarkers for combination therapy for er+ breast cancer WO2023172891A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263317411P 2022-03-07 2022-03-07
US63/317,411 2022-03-07

Publications (2)

Publication Number Publication Date
WO2023172891A2 WO2023172891A2 (en) 2023-09-14
WO2023172891A3 true WO2023172891A3 (en) 2023-10-19

Family

ID=87935904

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/063825 WO2023172891A2 (en) 2022-03-07 2023-03-07 Biomarkers for combination therapy for er+ breast cancer

Country Status (1)

Country Link
WO (1) WO2023172891A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140018433A1 (en) * 2012-07-13 2014-01-16 Gtx, Inc. Method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
WO2021055517A1 (en) * 2019-09-16 2021-03-25 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatments based upon molecular characterization of breast cancer
US20210186932A1 (en) * 2015-11-10 2021-06-24 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and anti-estrogen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140018433A1 (en) * 2012-07-13 2014-01-16 Gtx, Inc. Method of treating androgen receptor (ar) -positive breast cancers with selective androgen receptor modulator (sarms)
US20210186932A1 (en) * 2015-11-10 2021-06-24 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and anti-estrogen
WO2021055517A1 (en) * 2019-09-16 2021-03-25 The Board Of Trustees Of The Leland Stanford Junior University Methods of treatments based upon molecular characterization of breast cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PATEL HITISHA K., BIHANI TEERU: "Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment", PHARMACOLOGY & THERAPEUTICS, ELSEVIER., GB, vol. 186, 1 June 2018 (2018-06-01), GB , pages 1 - 24, XP055838151, ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2017.12.012 *
RAJC JASMINA, FRÖHLICH IRENA, MRČELA MILANKA, TOMAŠ ILIJAN, FLAM JOSIPA, : "Prognostic Impact of Low Estrogen and Progesterone Positivity in Luminal B (HER2 Negative) Breast Cancer", ACTA CLINICA CROATICA, SESTRE MILOSRDNICE UNIVERSITY HOSPITAL, ZAGREB, HR, 1 January 2018 (2018-01-01), HR , XP093103013, ISSN: 0353-9466, DOI: 10.20471/acc.2018.57.03.04 *
VARELLA LETICIA, CRISTOFANILLI MASSIMO: "Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date", ONCOTARGETS AND THERAPY, vol. Volume 16, 23 March 2023 (2023-03-23), pages 189 - 196, XP093103015, DOI: 10.2147/OTT.S400563 *

Also Published As

Publication number Publication date
WO2023172891A2 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
WO2022109339A8 (en) Use of dextramer in single cell analysis
MX2021009259A (en) Il-2 conjugates and methods of use thereof.
Fujii et al. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma
WO2019213282A8 (en) Biomarkers for evaluating car-t cells to predict clinical outcome
Iriondo et al. Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions
Heublein et al. The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients
MX2022001776A (en) Immuno oncology combination therapies with il-2 conjugates.
MX2022005091A (en) Methods of preparing an enriched sample for polypeptide sequencing.
WO2020252208A3 (en) Macrophage specific engager compositions and methods of use thereof
MX2022003212A (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use.
MX2022006655A (en) Use of cell free nucleosomes as biomarkers.
MX2022008099A (en) Treatment of cancer with cdk12/13 inhibitors.
WO2023172891A3 (en) Biomarkers for combination therapy for er+ breast cancer
MX2021008834A (en) Methods of treating breast cancer with tucatinib.
ZA202107139B (en) Methods and compositions for treating cancer
MX2022010461A (en) Methods for expanding t cells for the treatment of cancer and related malignancies.
EP4054406A4 (en) Systems, apparatus, and methods of analyzing specimens
ZA202206670B (en) Anti-ly6g6d antibodies and methods of use
WO2020064997A8 (en) Microbiota composition, as a marker of responsiveness to anti-pd1/pd-l1/pd-l2 antibodies in renal cell cancer
WO2022090801A3 (en) Pvrl2 and/or pvrig as biomarkers for treatment
CA3207182A1 (en) T cell therapy
MX2022006031A (en) Methods of treating cancer using dkk-1-inhibitors.
BR112022012885A2 (en) METHOD FOR TREATMENT OF A CANCER THAT EXPRESSES CD70 IN A SUBJECT, PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A CANCER THAT EXPRESSES CD70, E, KIT
WO2021067664A3 (en) Methods for targeted cell depletion
WO2020150751A3 (en) Devices and methods for tissue and cell staining (ii)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23767600

Country of ref document: EP

Kind code of ref document: A2